National Health (Price and Special Patient Contribution) Amendment Determination 2015 (No. 2) (PB 27 of 2015) (Cth)

PB 27 of 2015

National Health (Price and Special Patient Contribution) Amendment Determination 2015 (No. 2)

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

Dated 23 March 2015

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division
Department of Health

1          Name of Instrument

(1)        This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2015 (No. 2).

(2)        This Instrument may also be cited as PB 27 of 2015.

2          Commencement

This Instrument commences on 1 April 2015.

3          Amendment of the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

Schedule 1     Amendments

[1] Schedule 1, entry for Allopurinol in the form Tablet 100 mg [Pricing Quantity/Pack Quantity: 200]

omit from the column headed “Claimed Price”:          6.46        substitute:             6.91

[2] Schedule 1, entry for Allopurinol in the form Tablet 300 mg

omit from the column headed “Claimed Price”:          4.93        substitute:             5.39

[3] Schedule 1, entry for Ciprofloxacin in the form Tablet 250 mg (as hydrochloride)

omit from the column headed “Claimed Price”:          4.74        substitute:             5.55

[4] Schedule 1, entry for Ciprofloxacin in the form Tablet 500 mg (as hydrochloride)

omit from the column headed “Claimed Price”:          8.95        substitute:             9.67

[5] Schedule 1, entry for Citalopram

omit from the column headed “Claimed Price”:          4.96        substitute:             6.60

[6] Schedule 1, entry for Diazepam

omit from the column headed “Claimed Price”:          1.65        substitute:             3.07

[7] Schedule 1, entry for Glipizide

(a)   omit from the column headed “Determined Price”:             4.73        substitute:             6.34

(b)   omit from the column headed “Claimed Price”:                  8.38        substitute:             9.99

[8] Schedule 1, entry for Lactulose

insert in the columns in the order indicated and in alphabetical order for the column headed “Brand”:

Dulose 1 3.19 3.91

[9] Schedule 1, entry for Nifedipine in the form Tablet 10 mg

omit from the column headed “Claimed Price”:          5.88        substitute:             6.69

1. Schedule 1, entry for Nifedipine in the form Tablet 20 mg

   omit from the column headed “Claimed Price”:          7.66        substitute:             8.47

2. Schedule 1, entry for Nifedipine in the form Tablet 30 mg (controlled release)

   omit from the column headed “Claimed Price”:          8.66        substitute:             9.47

3. Schedule 1, entry for Nifedipine in the form Tablet 60 mg (controlled release)

   omit from the column headed “Claimed Price”:          10.64     substitute:             11.45

4. Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg

   omit from the column headed “Claimed Price”:          9.46        substitute:             10.26

5. Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg

   omit from the column headed “Claimed Price”:          17.79     substitute:             18.59

6. Schedule 1, omit entry for Polyvinyl Alcohol